SVF
Insufficient· Insufficient EvidenceNarrative Review

Osteoarthritic knee: Advances in Epidemiology, Emerging Etiopathologies and Adipose-Derived Stem Cells-based Therapies.

Lee CH., Lu HT., Chen KT., Wu SH., Su YF., Ting HH.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Chronic Inflammation, published in Aging Dis (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Aging Dis (2026)
Country
United States
Reported sample size
—
PMID
41619275
DOI
10.14336/AD.2025.1401

Abstract (original English)

Knee osteoarthritis (KOA) is a degenerative disorder that affects the joint in a non-uniform and focal manner. It is characterized by the loss of hyaline articular cartilage, along with bony remodeling, capsular stretching, and weakness of periarticular muscles. It could be ascribed to etiological factors that are modifiable (obesity, joint injury, occupational hazards, physical inactivity), non-modifiable (age, female gender, and genetic predisposition, racial/ethnic differences), or emerging, such as high blood pressure, vitamin D deficiency, and metabolic syndrome, which might contribute to KOA pathophysiology. KOA treatment is multimodal, and recent years have witnessed a shift from primarily pharmacologic, surgical to regenerative therapies ones, due to limited advantages of the former and evidence that advanced approaches are more likely to suppress pathological symptoms in the long term and to delay or prevent functional decline. Minimally invasive stem cell-based alternatives such as adipose-derived stem cells (ADSCs) are being explored owing to their differentiation potential towards chondro-, osteo-, and adipogenic lineages for osteochondral reparative regeneration. ADSC-derived extracellular vesicles, particularly exosomes (ADSC-exo), are gaining prominence in the treatment of KOA due to their unique regenerative and anti-inflammatory properties. These exosomes offer

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
KneeKnee OsteoarthritisOsteoarthritisCartilage DamageChronic Inflammation
View on PubMedDOI

Related research